【交银国际：升先声药业(02096.HK)目标价至16.4港元 维持“买入”评级】智通财经APP获悉，交银国际发布研报称，先声药业(02096.HK)上半年取得强劲的业绩增长，新产品快速放量、叠加BD合作收入，驱动创新药整体收入增长26%。展望未来三年，该行认为公司即将进入研发成果集中落地的关键拐点，体现在至少5款创新药/新适应症有望获批上市;更多早期资产/技术平台有BD合作潜力。该行将目标价由14.3港元升至16.4港元，维持买入评级及重点推荐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.